Literature DB >> 18594480

Therapeutic considerations in applying rate control therapy for atrial fibrillation.

D George Wyse1.   

Abstract

The therapeutic strategy of heart rate control for atrial fibrillation (AF) is undergoing a renaissance since several recent randomized trials demonstrated clear advantages over the rhythm control for many patients. Heart rate control for AF is hampered, however, by a dearth of information relating target heart rates to physiological measures or clinical outcomes. In this review, the rather sparse rationale behind the data elements for heart rate control - resting heart rate, activity heart rate, and regularity of the heart rate, is outlined. Beat-to-beat stroke volume is probably a key variable for calibrating heart rate targets. Presently it seems reasonable to propose targets for resting and activity heart rates but not for regularity. It also seems plausible but remains unproven that there should be a range (upper and lower) of heart rate targets rather than a simple upper limit. Nevertheless, it remains to be demonstrated through randomized clinical trials how to apply various heart rate control targets in patients with AF and whether complexity offers any advantage over simplicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594480     DOI: 10.1097/FJC.0b013e31816d5f49

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps.

Authors:  Jeffrey Triska; Juan Tamargo; Biykem Bozkurt; Uri Elkayam; Addison Taylor; Yochai Birnbaum
Journal:  Cardiovasc Drugs Ther       Date:  2022-03-31       Impact factor: 3.727

Review 2.  Redox regulation, NF-kappaB, and atrial fibrillation.

Authors:  Ge Gao; Samuel C Dudley
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

Review 3.  Rate control strategies for atrial fibrillation.

Authors:  Muath Alobaida; Abdullah Alrumayh
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

4.  Digoxin versus placebo, no intervention, or other medical interventions for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.

Authors:  Naqash J Sethi; Sanam Safi; Joshua Feinberg; Emil E Nielsen; Christian Gluud; Janus C Jakobsen
Journal:  Syst Rev       Date:  2017-04-05

5.  The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.

Authors:  Naqash J Sethi; Sanam Safi; Emil E Nielsen; Joshua Feinberg; Christian Gluud; Janus C Jakobsen
Journal:  Syst Rev       Date:  2017-03-06

Review 6.  Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.

Authors:  Naqash J Sethi; Emil E Nielsen; Sanam Safi; Joshua Feinberg; Christian Gluud; Janus C Jakobsen
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

7.  Atrial Fibrillation is Associated with Femoropopliteal Totally Occlusive In-Stent Restenosis: A Single-Center, Retrospective, Observational Study.

Authors:  Yohsuke Honda; Keisuke Hirano; Masahiro Yamawaki; Motoharu Araki; Norihiro Kobayashi; Yasunari Sakamoto; Shinsuke Mori; Masakazu Tsutsumi; Kenji Makino; Shigemitsu Shirai; Masafumi Mizusawa; Takahiro Nakano; Yoshiaki Ito
Journal:  J Interv Cardiol       Date:  2021-02-03       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.